방사선의학 웹진

바로가기  >

위 그림은 본 연구에서 확립된 대식세포 추적기술을 이용하여 염증 치료인 “덱사메타손”과 “GSK5182 (ERRγ inverse agonist)”가 효과적으로 대식세포의 염증부위 침윤을 억제함을 보여주고 있다.​

Abstract

Reliable and sensitive imaging tools are required to track macrophage migration and provide a better understating of their biological roles in various diseases. Here, we demonstrate the possibility of radioactive iodide-embedded gold nanoparticles (RIe-AuNPs) as a cell tracker for nuclear medicine imaging. To demonstrate this utility, we monitored macrophage migration to carrageenan-induced sites of acute inflammation in living subjects and visualized the effects of anti-inflammatory agents on this process. Macrophage labeling with RIe-AuNPs did not alter their biological functions such as cell proliferation, phenotype marker expression, or phagocytic activity. In vivo imaging with positron-emission tomography revealed the migration of labeled macrophages to carrageenan-induced inflammation lesions 3 h after transfer, with highest recruitment at 6 h and a slight decline of radioactive signal at 24 h; these findings were highly consistent with the data of a bio-distribution study. Treatment with dexamethasone (an anti-inflammation drug) or GSK5182 (an ERRγ inverse agonist) hindered macrophage recruitment to the inflamed sites. Our findings suggest that a cell tracking strategy utilizing RIe-AuNPs will likely be highly useful in research related to macrophage-related disease and cell-based therapies.

Author information

Lee SB1, Lee HW2, Singh TD2, Li Y3, Kim SK4, Cho SJ5, Lee SW1, Jeong SY2, Ahn BC2, Choi S6, Lee IK7, Lim DK8, Lee J9, Jeon YH10.​

1Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, South Korea;; Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu, South Korea.2Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, South Korea.3Department of Pathology, Chemon Co. Ltd., 240, Nampyeong-Ro, Yangji-Myeon, Cheoin-Gu, Yongin-Si, Gyeonggi-Do, 17162, Republic of Korea.4Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea.5New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea.6Department of Pharmacy, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA.7Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu, South Korea;; Department of Internal Medicine, Kyungpook National University School of Medicine, Deagu 700-721, South Korea.8KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul Anam-ro 145, South Korea.9Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, South Korea;; Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea.10Leading-edge Research Center for Drug Discovery and Development for Diabetes and Metabolic Disease, Kyungpook National University Hospital, Daegu, South Korea;; Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea.

관련자료보기

http://www.rmwebzine.re.kr/user/0029/nd54393.do?View&pageLS=10&page=1&pageSC=SORT_ORDER&pageSO=DESC&pageST=SUBJECT&boardNo=00001622